Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

1月12日，青岛华厦眼科医院在院内隆重举行"中医眼病门诊成立暨专家聘任仪式"。这标志着医院眼科 诊疗体系正式迈入"中西医深度融合"的新阶段，为广大眼病患者提供了一条更为多元、系统与个性化的 健康之路。 当前，国家正大力倡导中西医协同发展。青岛华厦眼科医院积极响应号召，在持续夯实西医眼科技术优 势的基础上，成立"中医眼病门诊"，前瞻性地布局中医眼科特色服务。这不仅是医院完善学科体系、推 动服务升级的重要战略，更是践行"一切以患者为中心"服务理念，回应民众对多层次、整合型医疗需求 的切实举措。 医院总经理汪洋在致辞中强调："成立中医眼病门诊是医院高质量服务的新起点，今后我们将全力支持 该门诊在临床、科研与人才队伍建设方面的发展，推动其与院内其他科室深度协同，最终构建起一个真 正覆盖'预防-治疗-康复'全周期、融合中西医学智慧的眼健康服务模式。" 门诊的发展离不开领军人才的带动。仪式上，医院正式聘任李庆副主任医师为中医眼病门诊学科带头 人。李庆主任深耕中医眼科多年，临床经验丰富，医术医德备受认可。她的加入，为这一新兴学科注入 了坚实的专业核心与发展信心。 "我们始终认为，现代医学与传统中医是相辅相成的伙伴关系，而非 ...

2026年1月5日，博士伦公司事业部总监Garry Lau、国药瑞德医疗器材有限公司总经理朱鼎宏一行到访 华厦眼科。集团领导陈凤国携相关部门负责人热情接待，围绕眼病手术领域的技术革新、临床应用与服 务质量提升，展开深度座谈交流。此次战略对话旨在进一步深化战略合作，共同探索眼病手术诊疗新模 式，推动眼病服务向更高品质、更精准、更可及的方向迈进。 共叙合作情谊，共话发展愿景 集团领导陈凤国对博士伦与国药瑞德一行的到访表示热烈欢迎。他指出，"一切以病人为中心"是华厦眼 科始终不变的服务宗旨。"十四五"期间，我国CSR(每百万人白内障手术例数)不断提高，但较发达国家 仍有较大差距。从长远看，提升眼病手术的普及率与技术水平仍是行业重要使命。 他强调，提升眼病手术诊疗服务质量是双方共同的责任与追求，期待通过更全面的资源整合，探索高品 质眼病服务新路径，造福更多眼疾患者。 博士伦事业部总监Garry Lau深情回顾，博士伦与华厦眼科是22载的"老朋友"，彼此的信任早已根深叶 茂。他表示，华厦眼科拥有顶尖的专家团队、强大的临床实力与广泛的基层医疗网络覆盖能力，是国内 眼科医疗领域的佼佼者，也是博士伦创新产品的优先合作伙伴。 ...

Group 1 - The core viewpoint of the news is that Huaxia Eye Hospital has shown a slight decline in stock price and has experienced significant financing activities, indicating a mixed sentiment among investors [1] - As of December 31, Huaxia Eye Hospital's stock price fell by 0.06%, with a trading volume of 55.95 million yuan. The net financing buy was -4.74 million yuan, indicating more financing repayment than buying [1] - The total financing and securities balance for Huaxia Eye Hospital reached 192 million yuan, with the financing balance accounting for 1.26% of the circulating market value, which is above the 90th percentile of the past year [1] Group 2 - As of September 30, the number of shareholders for Huaxia Eye Hospital increased to 21,200, a rise of 0.58%, while the average circulating shares per person decreased by 0.57% to 15,489 shares [2] - For the period from January to September 2025, Huaxia Eye Hospital reported a revenue of 3.272 billion yuan, reflecting a year-on-year growth of 2.83%, and a net profit attributable to shareholders of 434 million yuan, up by 3.04% [2] - Since its A-share listing, Huaxia Eye Hospital has distributed a total of 507 million yuan in dividends [3]

Group 1 - The core point of the news is that Huaxia Eye Hospital's stock has experienced a decline of 1.04%, with a total market value of 15.128 billion yuan and a cumulative drop of 0.6% over the last three days [1] - Huaxia Eye Hospital Group, established on August 12, 2004, specializes in ophthalmology services, with revenue composition as follows: refractive projects 36.90%, comprehensive optometry projects 24.04%, cataract projects 20.14%, posterior segment projects 12.94%, and others 5.99% [1] - The stock's trading volume was 36.5619 million yuan, with a turnover rate of 0.31% [1] Group 2 - Huaxia Eye Hospital's major circulating shareholder is Huabao Fund, which reduced its holdings in the Huabao CSI Medical ETF (512170) by 1.1664 million shares, now holding 7.1388 million shares, representing 2.17% of circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 1.3564 million yuan, with a cumulative floating loss of 785,300 yuan during the three-day decline [2] - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 26.404 billion yuan and a year-to-date return of 5.42%, ranking 3760 out of 4195 in its category [2]

证券日报网讯 12月29日，华厦眼科发布公告称，公司第三届董事会第十二次会议审议通过《关于公司 董事会换届选举暨提名第四届董事会非独立董事候选人的议案》《关于公司董事会换届选举暨提名第四 届董事会独立董事候选人的议案》《关于终止实施2025年员工持股计划的议案》等多项议案。 （编辑 丛可心） ...

证券日报网讯12月29日，华厦眼科（301267）发布公告称，公司将于2026年1月14日14：30召开2026年 第一次临时股东会，审议董事会换届选举非独立董事及独立董事议案，采用累积投票制，现场与网络投 票结合。 ...

格隆汇12月29日丨华厦眼科(301267.SZ)公布，鉴于行业集采政策、医保支付方式改革等客观因素仍对 公司经营产生影响，综合考虑市场环境因素和公司未来发展规划，公司预期经营情况与员工持股计划业 绩考核指标的设定存在偏差，继续实施本次员工持股计划将难以达到预期的激励目的和效果。从公司长 远发展和员工切身利益角度出发，结合参与员工的意愿以及公司的实际情况，经审慎研究，公司董事会 决定提前终止实施本次员工持股计划，同时一并终止与之配套的《2025年员工持股计划管理办法》等相 关文件。 ...

截至发稿，华厦眼科市值为153亿元。 （记者 张明双） 每经AI快讯，华厦眼科（SZ 301267，收盘价：18.2元）12月29日晚间发布公告称，公司第三届第十二 次董事会会议于2025年12月29日在公司会议室召开。会议审议了《关于终止实施2025年员工持股计划的 议案》等文件。 每经头条（nbdtoutiao）——绕开光刻机"卡脖子"，中国新型芯片问世！专访北大孙仲：支撑AI训练和 具身智能，可在28纳米及以上成熟工艺量产 2025年1至6月份，华厦眼科的营业收入构成为：屈光占比36.9%，眼视光综合项目占比24.04%，白内障 占比20.14%，眼后段项目占比12.94%，其他业务占比5.99%。 ...

华厦眼科医院集团股份有限公司 独立董事提名人声明与承诺 提名人华厦眼科医院集团股份有限公司董事会现就提名 王志强 为华 厦眼科医院集团股份有限公司第四届董事会独立董事候选人发表公开声明。被 提名人已书面同意作为华厦眼科医院集团股份有限公司第四届董事会独立董事 候选人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职 业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情 况后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规 范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要 求，具体声明并承诺如下事项： 一、被提名人已经通过华厦眼科医院集团股份有限公司第三届董事会提名 委员会资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规 定不得担任公司董事的情形。 （王志强） ☑ 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳 证券交易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 ...